Ablynx is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases. Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. The unique structure and stability of Nanobodies® has allowed Ablynx, and its partners, to pursue targets that are typically difficult to reach with conventional antibodies. The company is located in Ghent, Belgium.

Incorporated in 2002, Ablynx is a Belgium-based biopharmaceutical R&D company, spun out from VIB and the Vrije Universiteit Brussel.